Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

January 9, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806671/15459/en/Myriad-Genetics-Applauds-New-Germline-Testing-Guideline-for-Patients-with-Breast-Cancer-from-ASCO-SSO.html

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Read more at globenewswire.com

Related news for (MYGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.